Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression

Kruti Joshi, MPH; Joshua N. Liberman, PhD, MBA; Purva Parab, PhD; Jonathan D. Darer, MD, MPH; Lisa Harding, MD

J Clin Psychiatry 2024;85(2):23m15102

Abstract

Background: Under a risk evaluation and mitigation strategy program, esketamine nasal spray CIII requires self administration at a certified treatment center. Our objective was to identify factors associated with esketamine initiation and continuation.

Methods: A retrospective observational cohort study was conducted among US adults who met treatment-resistant depression (TRD) criteria. Cases (n = 966) initiated esketamine between October 11, 2019, and February 28, 2022, and were compared to controls (n = 39,219) with TRD but no esketamine use. Outcomes included initiation, induction (8 administrations within 45 days), and interruptions (30-day treatment gap). Comorbid psychiatric conditions were identified using International Classification of Diseases, Tenth Revision, Clinical Modification, codes.

Results: Cases resided significantly closer to treatment centers (8.9 vs 20.3 miles). Compared to 0–9 miles, initiation rate decreased by 11.9%, 50.8%, 68.1%, 75.9%, and 92.8% for individuals residing 10–19, 20–29, 30–39, 40–49, and 50+ miles from a center. After adjustment, factors associated with increased likelihood of initiation were posttraumatic stress disorder, major depressive disorder with suicidal ideation, and male sex, while increasing distance, substance use disorder, Medicaid, Charlson Comorbidity Index (CCI), and older age were associated with lower likelihood. Factors associated with lower likelihood of completing induction were Medicaid, low socioeconomic status (SES), CCI, and Hispanic communities. Factors associated with increased likelihood of interruption were alcohol use disorder, distance, and minority communities, while generalized anxiety disorder and Medicaid were associated with lower likelihood.

Conclusions: Travel distance, insurance, low SES, and minority communities are potential barriers to treatment. Alternative care models may be needed to ensure adequate access to care.

J Clin Psychiatry 2024;85(2):23m15102

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (40)

Zhdanava M, Pilon D, Ghelerter I, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82(2):20m13699. PubMed CrossRef
Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020;16:221–234. PubMed CrossRef
Brown S, Rittenbach K, Cheung S, et al. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews. Can J Psychiatry. 2019;64(6):380–387. PubMed CrossRef
Liu X, Mukai Y, Furtek CI, et al. Epidemiology of treatment-resistant depression in the United States. J Clin Psychiatry. 2021;83(1):21m13964. PubMed CrossRef
Nemeroff CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry. 2007;68(suppl 8):17–25. PubMed
Lundberg J, Cars T, Lööv SÅ, et al. Association of treatment-resistant depression with patient outcomes and health care resource utilization in a population-wide study. JAMA Psychiatry. 2023;80(2):167–175. PubMed CrossRef
Zhdanava M, Kuvadia H, Joshi K, et al. Economic burden of treatment-resistant depression in privately insured U.S. patients with physical conditions. J Manag Care Spec Pharm. 2020;26(8):996–1007. PubMed CrossRef
Office of the Commissioner, US Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Accessed November 1, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. PubMed CrossRef
Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. J Community Health. 2013;38(5):976–993. PubMed CrossRef
Elnitsky CA, Andresen EM, Clark ME, et al. Access to the US Department of Veterans Affairs health system: self-reported barriers to care among returnees of Operations Enduring Freedom and Iraqi Freedom. BMC Health Serv Res. 2013;13:498. PubMed CrossRef
Packness A, Waldorff FB, dePont Christensen R, et al. Impact of socioeconomic position and distance on mental health care utilization: a nationwide Danish follow up study. Soc Psychiatr Psychiatr Epidemiol. 2017;52(11):1405–1413. PubMed CrossRef
Drapalski AL, Milford J, Goldberg RW, et al. Perceived barriers to medical care and mental health care among veterans with serious mental illness. Psychiatr Serv. 2008;59(8):921–924. PubMed CrossRef
Sareen J, Jagdeo A, Cox BJ, et al. Perceived barriers to mental health service utilization in the United States, Ontario, and the Netherlands. Psychiatr Serv. 2007;58(3):357–364. PubMed CrossRef
US Census Bureau. One in five Americans live in rural areas. Census.gov. Accessed October 8, 2021. https://www.census.gov/library/stories/2017/08/rural-america.html
Andrilla CHA, Patterson DG, Garberson LA, et al. Geographic variation in the supply of selected behavioral health providers. Am J Prev Med. 2018;54(6 suppl 3):S199–S207. PubMed CrossRef
Morales DA, Barksdale CL, Beckel-Mitchener AC. A call to action to address rural mental health disparities. J Clin Transl Sci. 2020;4(5):463–467. PubMed CrossRef
Mojtabai R, Olfson M, Sampson NA, et al. Barriers to mental health treatment: results from the National Comorbidity Survey Replication. Psychol Med. 2011;41(8):1751–1761. PubMed CrossRef
Leong FTL, Kalibatseva Z. Cross-cultural barriers to mental health services in the United States. Cerebrum. 2011;2011:5. PubMed
Walker ER, Cummings JR, Hockenberry JM, et al. Insurance status, use of mental health services, and unmet need for mental health care in the United States. Psychiatr Serv. 2015;66(6):578–584. PubMed CrossRef
NAMI. The Doctor Is Out. NAMI; 2023. https://www.nami.org/Support-Education/Publications-Reports/Public-Policy-Reports/The-Doctor-is-Out/DoctorIsOut.
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40(5):373–383. PubMed CrossRef
Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. PubMed CrossRef
Eberhardt MS, Pamuk ER. The importance of place of residence: examining health in rural and nonrural areas. Am J Public Health. 2004;94(10):1682–1686. PubMed CrossRef
Probst JC, Laditka SB, Moore CG, et al. Rural-urban differences in depression prevalence: implications for family medicine. Fam Med. 2006;38(9):653–660. PubMed
Hoyt DR, Conger RD, Valde JG, et al. Psychological distress and help seeking in rural America. Am J Community Psychol. 1997;25(4):449–470. PubMed CrossRef
Brenes GA, Danhauer SC, Lyles MF, et al. Barriers to mental health treatment in rural older adults. Am J Geriatr Psychiatry. 2015;23(11):1172–1178. PubMed CrossRef
USDA. Rural Poverty & Well-Being. USDA; 2022. Accessed November 29, 2023. https://www.ers.usda.gov/topics/rural-economy-population/rural-poverty-well-being/
Zhao G, Okoro CA, Hsia J, et al. Prevalence of disability and disability types by urban–rural county classification—U.S., 2016. Am J Prev Med. 2019;57(6):749–756. PubMed CrossRef
Noh JW, Kwon YD, Park J, et al. Relationship between physical disability and depression by gender: a panel regression model. PLoS One. 2016;11(11):e0166238. PubMed CrossRef
Martin LR, Williams SL, Haskard KB, et al. The challenge of patient adherence. Ther Clin Risk Manag. 2005;1(3):189–199. PubMed
Corder JC. Streamlining the insurance prior authorization debacle. Mo Med. 2018;115(4):312–314. PubMed
Baudot J, Soeiro T, Tambon M, et al. Safety concerns on the abuse potential of esketamine: multidimensional analysis of a new anti-depressive drug on the market. Fundam Clin Pharmacol. 2022;36(3):572–581. PubMed CrossRef
Grant BF, Harford TC. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. Drug Alcohol Depend. 1995;39(3):197–206. PubMed CrossRef
Schuckit MA, Smith TL, Kalmijn J. Relationships among independent major depressions, alcohol use, and other substance use and related problems over 30 years in 397 families. J Stud Alcohol Drugs. 2013;74(2):271–279. PubMed CrossRef
Boden JM, Fergusson DM, Horwood LJ. Alcohol misuse and depression: results from a longitudinal general population study. J Abnorm Psychol. 2011;120(2):497–507. PubMed
McGuire TG, Miranda J. New evidence regarding racial and ethnic disparities in mental health: policy implications. Health Aff (Millwood). 2008;27(2):393–403. PubMed CrossRef
SAMHSA. Racial/ethnic differences in mental health service use among adults. Accessed September 7, 2023. https://www.samhsa.gov/data/sites/default/files/MHServicesUseAmongAdults/MHServicesUseAmongAdults.pdf
Liberman J, Pesa J, Rui P, et al. Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder. Medicine (Baltimore). 2023;102(7):e32895. PubMed CrossRef
Walkup JT, Townsend L, Crystal S, et al. A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data. Pharmacoepidemiol Drug Saf. 2012;21(21 suppl 1):174–182. PubMed CrossRef